Recently, the first patient dosing of Xinyue (Inebilizumab Injection), Hansoh Pharma's drug for the rare disease neuromyelitis optica spectrum disorders (NMOSD), was completed at the First Affiliated Hospital of Zhejiang University School of Medicine in China, marking the entry of the world's only anti-CD19 McAb for NMOSD in China's clinical application and opening a new chapter in the treatment of adult patients with NMOSD in China.

Inebilizumab was introduced into China by Hansoh Pharma in 2019, listed as a Class A recommended drug in China's Guidelines for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (2021) in December 2021, approved for marketing by the National Medical Products Administration (NMPA) in March 2022, and included in the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2022) on January 18, 2023, and its first patient dosing was completed on January 30, 2023. Every step of its launch in China reflects the country's fast speed to accelerate the accessibility of breakthrough and innovative drugs.

NMOSD is a rare autoimmune disease of nervous system, mainly involving optic nerve and spinal cord, and characterized by high recurrence and high disability. China currently has the largest NMOSD patient base in the world. Evidence-based proof shows that inebilizumab depletes B cells more extensively and sustainably, consistently reducing the risk of NMOSD recurrence; and it lowers the risk of worsening disability, is safe and reliable, and brings new hope to patients with limited treatment options.

Looking ahead, Hansoh Pharma will leverage the global innovation ecosystem, work towards the goal of meeting urgent clinical needs, accelerate the pace of scientific and technological innovation, explore and develop more new and good drugs, and contribute to the Healthy China 2030 initiative.